Combination therapy for colorectal cancer with liver tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of three drugs for patients with colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have colorectal cancer that has spread to your liver, and you have at least one measurable tumor in the liver.
- Your cancer is a type called MSS (microsatellite stable), which means it does not have a certain genetic marker that makes it respond to some immunotherapies.
- You have already received at least one round of chemotherapy that included fluorouracil, oxaliplatin, and irinotecan, and possibly other targeted drugs like bevacizumab or an EGFR inhibitor.
- You are generally able to take care of yourself (ECOG performance status 0 or 1) and have a life expectancy of at least 12 weeks.
- Your blood counts, kidney, and liver functions are within acceptable ranges.
- You have not received immunotherapy (like PD-1 or PD-L1 inhibitors) before.
- You do not have major heart disease, uncontrolled infections, active autoimmune disease, or other serious conditions that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
This trial tests a combination of two targeted drugs (sintilimab and bevacizumab) with chemotherapy for people whose colorectal cancer has not spread to the liver. It aims to see if this combo helps control the cancer better after the first treatment stops working.
This study tests a new drug combination (BioTTT001, toripalimab, and regorafenib) for people with colorectal cancer that has spread to the liver and has not responded to earlier treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests the combination of two immunotherapy drugs (botensilimab and balstilimab) plus targeted radiation to liver tumors. It's for people with colorectal cancer that has spread and hasn't responded to standard treatments.
This trial is testing a combination of a new immunotherapy drug (QL1706) with chemotherapy and either cetuximab or bevacizumab for people with colorectal cancer that has spread to the liver and can potentially be removed by surgery. The goal is to shrink the tumors before surgery, making them easier to remove.
This trial tests a new combination of treatments for colorectal cancer that has spread to the liver. It combines a special type of radiation therapy (called PULSAR) with immunotherapy and chemotherapy plus a drug that targets blood vessels, to see if it helps shrink tumors and improve outcomes.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.